BioSpace News Archive

Predicine provides an integrated oncology biomarker solution that includes an innovative RNA+DNA liquid biopsy test and a one-stop biomarker and data analysis platform to support targeted cancer therapeutics and global clinical trials.

Part of an eight-year commitment to WFH; Changing the lives of people with hemophilia in 47 countries with limited access to treatment

Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model

- Update on Ongoing MGMT-unmethylated Clinical Trials to be Presented on Tuesday April 17, 2018 -

Meniscus surgery is one of the most common surgical procedures in the United States, with one million performed annually

Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors

KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1 Results Presented Today at AACR 2018 and Published in The New England Journal of Medicine Also Show Significant Improvement in Progression-Free Survival, with Risk of Progression or Death Reduced by Nearly Half

Carlo W. Colesanti, President and CEO, announced today the launch of NextPhase Medical Devices LLC

Genomma Lab invites you to its First Quarter Conference Call and Webcast.

Enclara team presents full demo of pharmacy, DME and medical supply services at NHPCO MLC conference